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Key questions
What is already known about this subject?
 ► The success of molecularly guided cancer therapies 
can be measured using intra- patient progression- 
free survival (PFS) ratios, which are increasingly 
being used in clinical trial design.
What does this study add?
 ► The current study investigates the real- life assess-
ments of clinical benefits to molecularly guided 
cancer therapies based on a survey among in 100 
physicians involved in cancer care.
 ► Our findings led to the development of a new clinical 
endpoint, the modified PFS ratio.
How might this impact on clinical practice?
 ► The modified PFS ratio may be used as a novel, clin-
ically relevant endpoint for future precision oncology 
trials.
ABSTRACT
Objective Measuring the success of molecularly guided 
therapies is a major challenge in precision oncology trials. 
A commonly used endpoint is an intra- patient progression- 
free survival (PFS) ratio, defined as the PFS interval 
associated with molecularly guided therapy (PFS2) divided 
by the PFS interval associated with the last prior systemic 
therapy (PFS1), above 1.3 or, in some studies, above 1.33 
or 1.5.
Methods To investigate if the concept of PFS ratios is in 
agreement with actual response evaluations by physicians, 
we conducted a survey among members of the MASTER 
(Molecularly Aided Stratification for Tumor Eradication 
Research) Programme of the German Cancer Consortium 
who were asked to classify the success of molecularly 
guided therapies in 194 patients enrolled in the MOSCATO 
01 trial based on PFS1 and PFS2 times.
Results A comparison of classification profiles revealed 
three distinct clusters of PFS benefit assessments. 
Only 29% of assessments were consistent with a PFS 
ratio threshold of 1.3, whereas the remaining 71% of 
participants applied a different classification scheme that 
did not rely on the relation between PFS times alone, but 
also took into account absolute PFS1 intervals. Based on 
these community- driven insights, we developed a modified 
PFS ratio that incorporates the influence of absolute PFS1 
intervals on the judgement of clinical benefit by physicians. 
Application of the modified PFS ratio to outcome data from 
two recent precision oncology trials, MOSCATO 01 and 
WINTHER, revealed significantly improved concordance 
with physician- perceived clinical benefit and identified 
comparable proportions of patients who benefited from 
molecularly guided therapies.
Conclusions The modified PFS ratio may represent a 
meaningful clinical endpoint that could aid in the design 
and interpretation of future precision oncology trials.
IntROduCtIOn
Technological and methodological advances 
in medicine create opportunities to re- eval-
uate the standard of care and open new 
ways to differentiate between success and 
failure of individual therapies. In oncology, 
these changes are taking place at breath-
taking speed, for example, in the form of 
next- generation sequencing and advances 
in targeted and immunotherapies, and while 
physicians still struggle to implement these 
new developments into clinical routine, novel 
technologies are already looming on the 
horizon.1
To assess the efficacy of new drugs, medical 
oncology relies on statistical methods and 
evidence- based principles that were devel-
oped in the 1980s and have been continu-
ously advanced and refined since that time. 
Clinical endpoints acceptable for marketing 
approval are specified in the regulatory 
guidelines of the US Food and Drug Admin-
istration (Clinical Trial Endpoints for the 
Approval of Cancer Drugs and Biologics) 
as well as the European Medicines Agency 
(guideline on the evaluation of anticancer 
medicinal products in man), and although 
most therapeutic trials adhere to this frame-
work, there is growing awareness among clini-
cians that mere statistical improvement might 
not represent meaningful clinical benefit. As 
a consequence, several auxiliary scales and 
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scores have been developed to measure clinical benefit,2 
while overall survival in a randomised controlled trial 
(RCT) remains the most important endpoint in medical 
oncology.3 In addition, surrogate endpoints such as objec-
tive response rate, time to progression (TTP), progression- 
free survival (PFS) as well as symptom control nowadays 
belong to the standard set of tools for clinical trial design.
With the advent of precision oncology, broadly defined 
as a strategy to stratify cancer treatment based on molec-
ular data generated by, for example, next- generation 
sequencing,4 it has become clear that established clinical 
endpoints might not be sufficient to assess the efficacy of 
individualised therapies. This is mainly attributable to the 
unique molecular profiles of individual tumours, which 
preclude the compilation of adequately sized uniform 
patient cohorts required for a RCT. In addition, a placebo 
or standard- of- care arm may be considered unethical 
when testing a highly effective targeted drug in patients 
with advanced- stage cancers who have exhausted conven-
tional treatment options. Thus, the established frequen-
tist, non- Bayesian approach to the statistical design and 
assessment of clinical trials is difficult to reconcile with 
the principles of precision oncology. This dilemma was 
first recognised by Von Hoff and colleagues who devel-
oped the growth modulation index, or PFS ratio (PFSr), 
as a surrogate measure of treatment benefit and novel 
endpoint for precision oncology studies.5 6 Paired anal-
ysis of individual patients through assessment of the TTP 
or PFS during and after molecularly guided treatment 
(TTP2 or PFS2) in relation to the TTP or PFS during 
and after the last prior systemic therapy (TTP1 or PFS1) 
better accounted for the interindividual heterogeneity 
of tumours, patients, and responses to specific drugs. 
This approach, where each patient serves as his/her own 
control, circumvents the need for a control arm and 
has been widely adopted in current precision oncology 
trials.7–9 Despite some methodological concerns,10 several 
fixed PFSr (1.3, 1.33, 1.5) have been used as thresholds 
for the assessment of clinical benefit in recent studies.7 8
In this study, we have analysed the strengths and weak-
nesses of the PFSr as an endpoint in precision oncology 
trials. Specifically, we describe a community- driven effort 
towards an improved, modified PFSr (mPFSr) that faith-
fully represents the judgement of therapeutic benefit 
by clinicians from multiple institutions and validate the 
model on available clinical data.
MateRIal and MetHOds
survey on clinical benefit assessments based on PFs times
To investigate if the concept of PFSr is in line with actual 
response evaluations by clinicians, we reached out to 
referring and/or collaborating physicians within the 
MASTER (Molecularly Aided Stratification for Tumor 
Eradication Research) Programme of the German Cancer 
Consortium11 with a classification task. The survey was 
based on PFS times associated with molecularly guided 
therapies within the MOSCATO 01 precision oncology 
trial7 (figure 1A), and participants were asked to cate-
gorise patients as ‘responder’ or ‘non- responder’ based 
on PFS1 and PFS2 (figure 1B). We deliberately provided 
no guidelines for evaluation of the data but explicitly 
requested the participants’ individual response assess-
ment. Alongside the classification, we collected informa-
tion on the physicians’ profiles, including age, years of 
practice, and regular participation in molecular tumour 
boards (online supplementary table S1). We received 100 
complete replies, which were included in the analysis.
statistical analyses
Statistical analyses were carried out in R (V.3.5.2) with the 
extended functionality of the tidyverse package (V.1.2.1).12 
The binary heatmap was generated using the Complex-
Heatmap package (V.1.99.8).13 The alluvial plot was drawn 
with the ggalluvial package (V.0.9.1). Statistical signifi-
cance was assessed using t- tests or a Wilcoxon signed- rank 
test; *p<0.05, **p<0.01, ***p<0.001.
Results
Physician-perceived clinical benefit of molecularly guided 
therapies
To assess the congruence of response evaluations by 
physicians, we first calculated the fraction of votes classi-
fying a case as responder. Visualising the distribution of 
fractions (figure 1C) revealed distinct peaks at 0 (cate-
gorisation as responder by 0% of participants) and 1 
(categorisation as responder by 100% of participants), 
indicating general agreement among physicians in the 
perceived clinical benefit of molecularly guided thera-
pies. However, approximately 25% of cases were catego-
rised as responder or non- responder by a similar number 
of survey participants.
Cluster analysis revealed three distinct groups of classi-
fications (figure 1D). Interestingly, only 29% of classifica-
tions were consistent with a PFSr threshold of 1.3 (Cluster 
3), whereas the remaining 71% of physicians applied a 
significantly different classification scheme (p<0.001, 
figure 1E). For example, Cluster 1 was characterised by 
a significantly higher fraction of responders (p<0.001, 
figure 1F). Neither age or years of practice of the survey 
participants were significantly associated with member-
ship to a specific cluster. However, physicians that only 
occasionally participate in molecular tumour boards were 
enriched in Cluster 2 (p=0.039, online supplementary 
table S2).
discordance between physician-perceived clinical benefit and 
PFsr threshold
Next, we systematically analysed the discordance between 
physician- perceived clinical benefit, which was consid-
ered as the ground truth, and a PFSr threshold of 1.3. 
As expected, the physician classifications were signifi-
cantly associated with PFS2 duration (r=0.79, p<2.2E-16); 
however, there was a discordance between the majority 
vote of the physicians (responder class fraction >0.5) 
and the PFSr threshold (figure 2A) in 16% of cases 
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Figure 1 Physician- perceived clinical benefit of molecularly guided therapy. (A) PFS1 and PFS2 times of 194 patients 
enrolled in the MOSCATO 01 trial. (B) Examples of response assessments by physicians based on PFS1 and PFS2 times. 
(C) Distribution of fraction of responder class assignments. For example, a fraction of 1 denotes that all physicians classified 
the respective case as responder to molecularly guided therapy. (D) Binary heatmap of response classifications (rows) by 
100 physicians (columns) showing three distinct clusters of assessments (k- means clustering with k=3). Classifications were 
stratified by PFSr threshold. Stacked bar plots indicate the sum of response classifications (bottom). (E) Boxplots comparing 
the row- wise fraction of responder class assignments by physicians between the three clusters. (F) Boxplots comparing the 
concordance of response classifications by physicians with the class defined by a PFSr above 1.3 between the three clusters. 
*p<0.05, **p<0.01, ***p<0.001. PFS, progression- free survival; PFSr, PFS ratio.
(false positive, 9%; false negative, 7%; figure 2B,C). To 
understand these discrepancies, we looked into associa-
tions between incorrect classifications and PFS duration 
and observed that false positive cases were attributable to 
very short PFS1 times of less than 2 months, whereas false 
negative cases could be explained by similarly long PFS1 
and PFS2 times resulting in low PFSr values (figure 2D).
Community-driven definition of a modified PFsr
The analysis of response classifications by physicians 
revealed two major limitations of the current PFSr. On 
one hand, the clinical benefit of molecularly guided 
therapies will be overestimated if the PFS1 duration is 
very short. For example, a patient whose PFS1 and PFS2 
times are 1 and 2 months, respectively, will be classified as 
deriving clinical benefit based on a PFSr of 2. On the other 
hand, the efficacy of a molecularly guided therapy might 
be undervalued if the PFS1 and PFS2 intervals are iden-
tical. For example, a patient whose PFS1 and PFS2 times 
are both 12 months will be classified as non- responder 
based on a PFSr of 1. To overcome these limitations, we 
propose a modified PFSr (mPFSr; figure 3A, equation 1) 
that comprises two simple modifications to the conven-
tional PFSr. First, to adjust for false positives, all PFS1 
times below 2 months are converted into a modified PFS1 
interval, termed pre- PFS, of 2 months (figure 3A, equa-
tion 2). Second, to correct for false negative results, PFS2 
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Figure 2 Discordance between physician- perceived clinical benefit and PFSr threshold. (A) Fraction of cases classified 
as responders plotted over PFS2 time, coloured according to PFSr. (B) Fraction of cases classified as responders plotted 
over PFS2 time, coloured according to discordance between physician classification, which was considered as the ground 
truth, and PFSr threshold. (C) PFS2 time plotted over PFS1 time, coloured according to discordance between physician 
classification and PFSr threshold. (D) PFSr plotted over PFS2 (top) and PFS1 (bottom), coloured according to discordance 
between physician classification and PFSr threshold. PFS, progression- free survival; PFSr, PFS ratio.
times above 6 months are assumed to reflect successful 
moleculary guided therapy and are set to 24 months 
(post- PFS), resulting in PFSr above the currently used 
thresholds of 1.3, 1.33, or 1.5.
Comparative analysis of PFsr and mPFsr
To investigate whether the mPFSr more accurately 
reflects the clinical benefit of molecularly guided thera-
pies, we compared the survey results with the categori-
sation of patients based on a PFSr or mPFSr threshold 
of 1.3 and observed that the concordance with the physi-
cian classification was significantly higher for the mPFSr 
(figure 3B). Furthermore, application of the mPFSr to 
the outcome data of two recent precision oncology trials, 
MOSCATO 01 and WINTHER,7 8 identified comparable 
proportions of patients who benefited from molecularly 
guided therapies (33% vs 31% and 24% vs 24%, respec-
tively; figure 3C,D).
dIsCussIOn
In recent years, several precision oncology trials have 
used a PFSr as the primary endpoint. For example, the 
MOSCATO 01 study applied a PFSr threshold of 1.3 to 
detect a clinical benefit of molecularly targeted therapies 
in 33% of patients.7 The negative SHIVA study, on the other 
hand, the first randomised trial of molecularly targeted 
cancer therapy versus treatment of physician’s choice, 
was one of the few precision oncology trials that did not 
use a PFSr but a standard PFS endpoint.14 Nevertheless, 
this study highlighted important challenges of precision 
oncology in identifying histology- independent oncogenic 
drivers, in delivering clinically effective targeted therapies, 
and in adequate trial design.15 All the more interesting, a 
secondary, retrospective cross- over analysis of the SHIVA 
data revealed that 37% of patients who received molecu-
larly targeted therapy after progression on prior systemic 
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Figure 3 Definition of a mPFSr. (A) Algebraic definition of a mPFSr. In contrast to standard PFSr, the PFS2 interval is divided 
by the so- called prePFS time to correct for false positive predictions. In addition, PFS2 times above 6 months are set to 24 
months to correct for false negatives (postPFS). (B) Boxplots comparing the concordance with the physician classification 
between PFSr and mPFSr. *p<0.05, **p<0.01, ***p<0.001. (C, D) Alluvial diagrams comparing the classification of patients from 
the MOSCATO 01 (C) and WINTHER (D) trials according to PFSr and mPFSr thresholds of 1.3. mPFSr, modified PFSr; PFS, 
progression- free survival; PFSr, PFS ratio.
treatment had a PFSr above 1.3.16 The recently published 
WINTHER trial aimed to achieve a PFSr of more than 
1.5 in at least 50% of patients (40% for therapies based 
on RNA sequencing data). While this ambitious primary 
endpoint was not met, WINTHER demonstrated for the 
first time the feasibility of international prospective preci-
sion oncology trials.8 Despite its increasing popularity, 
the PFSr has been systematically investigated only in a 
handful of studies.10 17–20
We aimed to understand how the PFSr relates to 
physician- perceived clinical benefit, as judged based on 
PFS1 and PFS2 times alone. In addition to several clusters 
of PFS benefit evaluations, we identified PFS2/PFS1 rela-
tionships that likely result in false positive or false nega-
tive classifications when applying a fixed PFSr threshold. 
Specifically, most false positive assessments were caused 
by short PFS1 times of less than 2 months, whereas false 
negative assignments could be attributed to PFS2 and 
PFS1 intervals of equal length. On the basis of these 
community- driven insights, we developed a mPFSr that 
better reflects the clinical benefit assessment of physi-
cians involved in cancer care, and reanalysis of outcome 
data from published precision oncology studies7 8 using 
the mPFSr revealed a comparable proportion of patients 
who benefited from molecularly guided therapies.
In summary, we believe that the mPFSr represents a 
meaningful clinical endpoint that will aid in the design 
and interpretation of future precision oncology trials. 
There remain a number of important tasks, such as the 
application of uniform response evaluation criteria, 
systematic quality- of- life assessments, and the consider-
ation of PFS times prior to PFS1, and we are confident 
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that current efforts to meet these challenges will yield the 
next generation of outcome measures.
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